Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 26;9(1):34.
doi: 10.1186/s13195-017-0256-8.

Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study

Karim Tifratene  1   2 , Valeria Manera  1 , Roxane Fabre  1   2 , Auriane Gros  1   3 , Susanne Thummler  1 , Christian Pradier  2 , Philippe Robert  1   3 , Renaud David  4   5   6
Affiliations

Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study

Karim Tifratene et al. Alzheimers Res Ther. .

Abstract

Background: Safety warnings from health authorities are currently intended to limit the use of antipsychotics (APs) in dementia-related conditions to treat neuropsychiatric symptoms, such as disturbing and/or delusional behaviors. The aim of this study is to investigate prevalence, correlates and trends of AP prescribing among people with dementia between 2010 and 2014 in the French population.

Methods: AP prescribing and associated factors among individuals with AD, mixed dementia and vascular dementia in the French National Alzheimer Database between 2010 and 2014 were analyzed using multivariate generalized estimating equations models (n = 199,549).

Results: In 2014, 7.7% of people with dementia were prescribed an AP. Compared with 2010 there was a 16% increase in AP use. Multivariate analysis showed a linear increase risk of prescription with an adjusted odds ratio (95% confidence interval) of 1.23 (1.17-1.30) in 2014 compared with 2010. Factors associated with AP prescribing were male gender, more severe cognitive decline and living in long-term care facilities. Older age and higher education were protective toward AP prescribing. The type of dementia did not have any influence on AP prescribing.

Conclusion: An increase in AP prescribing among individuals with dementia in French specialized settings over the last 5 years occurred despite safety warnings. This phenomenon suggests that alternative solutions for the management of behavioral and psychiatric symptoms in these populations are still urgently needed.

Keywords: Alzheimer’s disease; Antipsychotics; Dementia; Drug prescribing; French Alzheimer Database.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Selection of participants included in the study. aThe same individual could account for different years. When considering a single year, an individual can only be counted once. AD Alzheimer’s disease, BNA Banque Nationale Alzheimer, MD mixed dementia, MMSE Mini Mental State Examination, VD vascular dementia
See this image and copyright information in PMC

References

    1. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245–55. doi: 10.1038/nrneurol.2009.39. - DOI - PubMed
    1. Burns A, Ballard C. A best practice guide for health and social care professionals. London: Alzheimer's Society; 2013.
    1. Bonner AF, Field TS, Lemay CA, Mazor KM, Andersen DA, Compher CJ, et al. Rationales that providers and family members cited for the use of antipsychotic medications in nursing home residents with dementia. J Am Geriatr Soc. 2015;63(2):302–8. doi: 10.1111/jgs.13230. - DOI - PubMed
    1. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatr. 2014;22(4):321–31. doi: 10.1016/j.jagp.2013.06.007. - DOI - PubMed
    1. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608. doi: 10.1001/jama.293.5.596. - DOI - PubMed

MeSH terms

Substances